重症肌无力:免疫检查点抑制剂的一种新兴毒性
本文综述免疫检查点抑制剂相关重症肌无力(MG)的文献并报告一例帕博利珠单抗诱导的MG新病例。23例报告病例中72.7%为新发、18.2%为原有MG加重、9.1%为亚临床MG加重;症状平均于治疗开始6周内出现(范围2-12周),乙酰胆碱抗体滴度升高与MG发生无一致关联,MG特异性相关死亡率为30.4%。
要点
- 免疫检查点抑制剂相关MG症状平均于治疗开始6周内出现(范围2-12周)。
- 23例中72.7%为新发MG,18.2%为原有MG加重,9.1%为亚临床MG加重。
- 乙酰胆碱抗体滴度升高与免疫检查点抑制剂相关MG发生无一致关联。
核心结论
- 免疫检查点抑制剂相关MG虽相对少见,但MG特异性相关死亡率达30.4%,早期识别和积极治疗至关重要。
研究设计与样本
- 综述现有文献并报告一例帕博利珠单抗诱导的重症肌无力新病例,纳入23例报告病例分析。
主要发现
- 23例免疫检查点抑制剂相关MG中,72.7%为新发表现,18.2%为原有MG加重,9.1%为亚临床MG加重。
- 症状平均于治疗开始6周内出现(范围2-12周)。
- 乙酰胆碱抗体滴度升高与免疫检查点抑制剂相关MG的发生无一致关联。
- MG特异性相关死亡率为30.4%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The advent of immunotherapy has heralded a number of significant advances in the treatment of particular malignancies associated with poor prognosis (melanoma, non-small-cell lung, renal and head/neck cancers). The success witnessed with therapeutic agents targeting cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 and programmed cell death ligand 1 immune checkpoints has inevitably led to an explosion in their clinical application and the subsequent recognition of specific toxicity profiles distinct from those long recognised with chemotherapy. Consequently, as the utility of such therapies broaden, understanding the nature, timing and management of these immune-related adverse events (irAEs) becomes increasingly significant. Although neurological irAEs are considered relatively rare in comparison with hepatitis, colitis, pneumonitis and endocrinopathies, one emerging side-effect is myasthenia gravis (MG). Among the 23 reported cases of immune checkpoint inhibitor-associated MG, 72.7% were de novo presentations, 18.2% were exacerbations of pre-existing MG and 9.1% were exacerbations of subclinical MG. The average onset of symptoms was within 6 weeks (range 2-12 weeks) of treatment initiation. In addition, there was no consistent association with elevated acetylcholine antibody titres and the development of immune checkpoint inhibitor-related MG. Significantly, there was a 30.4% MG-specific-related mortality, which further emphasises the importance of early recognition and robust treatment of this toxicity. In addition to a review of the existing literature, we present a new case of pembrolizumab-induced MG and provide insights into the underlying mechanisms of action of this phenomenon.
引用
- Makarious D, Horwood K, Coward JIG, et al. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017. PMID: 28666240. doi:10.1016/j.ejca.2017.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。